PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 11, 2026Asian Pacific Journal of Cancer Prevention0 citationsOpen Access

Clinical Significance of the S348l Mutation in BCR-ABL as a Dominant Variant in Indonesian CML Patients Under Tyrosine Kinase Inhibitor Therapy: A Cohort Study

THTutik HarjiantiWPWahyudi PabbabariFBFachruddin Benyamin

Key Points

  • The study aims to evaluate the impact of the S348L mutation in BCR-ABL on survival outcomes in CML patients undergoing TKI therapy.
  • Cohort study with Indonesian CML patients
  • Evaluation of survival outcomes post-TKI therapy
  • Assessment of mutation presence and type
  • Early hematological response to TKI therapy linked to better survival outcomes
  • S348L mutation identified as the most prevalent variant in the cohort
  • Presence of BCR-ABL mutations associated with poorer survival outcomes

Abstract

CML patients achieving early hematological response to TKI therapy had significantly better survival outcomes. In contrast, non-responders, particularly those harboring BCR-ABL kinase domain mutations, demonstrated poorer survival. The S348L mutation was the most common variant in this cohort. Early mutation detection may help guide therapeutic adjustments and improve outcomes in TKI-resistant CML.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Harjianti et al. (2026) studied this question.

synapsesocial.com/papers/698c1bef267fb587c655de86https://doi.org/10.31557/apjcp.2026.27.2.715
Ask AI
Helpful
Bookmark
Share
View Full Paper